Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. Read More It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.